


# İNDOSİYANİN YEŞİLİ ANJİYOGRAFİ

*Ali Atakhan YILDIZ<sup>1</sup>*

## 1. Giriş

İndosiyanın yeşili anjiyografi (İYA) ilk defa 1970'lerin başında Flower ve Hochheimer tarafından kullanıma girmiş ve 1975'de Amerikan İlaç ve Gıda Komitesi (FDA) onayı almıştır (1). İlk İYA kamera 1980'de, ilk video anjiyografi ise 1990'da piyasaya sürülmesine rağmen İYA'nın dünyada yaygın kullanıma girmesi 2000'li yıllardan sonra olmuştur. Kızılötesi dijital fotoğrafın ve tarayıcı lazer oftalmoskopun sisteme dahil olması ile görüntü çözünürlüğü ve kontrastı belirgin şekilde artmıştır. 2000'li yılların başından itibaren İYA kullanım alanı giderek artmış, koryoretinal hastalıkların patofizyolojisini anlamada ve tedavi takibinde önemli bir konuma gelmiştir. İndosiyanın yeşili anjiyografi, koroidal kan akımını görüntülemeye optik koherens tomografi (OKT), fundus floresin anjiyografi (FFA) ve otofloresans görüntülemeye üstün olmakla birlikte yüksek maliyetli ve girişimsel olma gibi dezavantajları bulunmaktadır. İndosiyanın yeşili anjiyografinin fiziksel özellikleri nedeniyle melanin ve ksantofil pigmentine, seröz-anjinöz sıvıya ve lipid eksüdaya nüfuz ederek koroidin net şekilde görüntülenmesini sağlamaktadır (2). Diğer taraftan polipoidal koroidal vaskülopati, retinal anjiomatöz proliferasyon (RAP), sessiz koroidal neovasküler membran (KNV) gibi retinal ve koroidal hastalıkların takibinde halen değerli bir görüntüleme yöntemidir.

<sup>1</sup> Op. Dr. Ali Atakhan YILDIZ, Bursa Özel Medicabil Hastanesi atoyildiz@hotmail.com



**Şekil 11:** Subfoveal koroidal sarkoidoz granülomu tanılı bir olgunun erken (a), orta (b) ve geç fazda (c) FFA (soldaki görüntüler) ile eşzamanlı İYA (sağdaki görüntüler) görüntüleri izlenmekte. Subfoveal alandaki odak; FFA'da hiperfloresan, İYA'da ise hipofloresan olarak izlenmekte. Ayrıca, İYA'da FFA'da dikkati çekmeyen periferel hipofloresan noktasal tutulumlar da görülebilmektedir. (Bursa Retina Göz Hastanesi Arşivi'nden alınmıştır.)

## 7. Özet

Son dönemde; OKTA gibi noninvazif görüntüleme yöntemlerinin kullanıma girmesi ve koroidal neovasküler membran tedavisinde anti-VEGF ajanların ön plana çıkması ile İYA'da lezyon lokalizasyonu öneminin azalmasına rağmen, koroidal vasküler yapının görüntülenmesinde ve PKV tanısında altın standart halen İYA'dır.

## Kaynaklar

1. Flower RW, Hochheimer BF. Clinical infrared absorption angiography of the choroid. *Am J Ophthalmol.* 1972;73:458–9.
2. Cohen SY, Dubois L, Quentel G, et al. Is indocyanine green angiography still relevant? *Retina* 2011;31:209–21.
3. Ott P. Hepatic elimination of indocyanine green with special reference to distribution kinetics and the influence of plasma protein binding. *Pharmacol Toxicol* 1998;83(2):1–48.
4. Luty GA. The acute intravenous toxicity of biological stains, dyes, and other fluorescent substances. *Toxicol Appl Pharmacol* 1978;44:225–49.
5. Bischoff PM, Flower RW. Ten years experience with choroidal angiography using indocyanine green dye: a new routine examination or an epilogue? *Doc Ophthalmol*

- 1985;60:235–91.
6. Geeraets WJ, Berry ER. Ocular spectral characteristics as related to hazards from lasers and other light sources. *Am J Ophthalmol* 1968;66:15–20.
  7. Caesar J, Shaldon S, Chiandussi L, et al. The use of indocyanine green in the measurement of hepatic blood flow and as a test of hepatic function. *Clin Sci* 1961;21:43–57.
  8. Leevy CM, Bender J. Physiology of dye extraction by the liver: comparative studies of sulfobromophthalein and indocyanine green. *Ann N Y Acad Sci* 1963;111:161–76.
  9. Costa DL, Huang SJ, Orlock DA, et al. Retinal-choroidal indocyanine green dye clearance and liver dysfunction. *Retina* 2003;23:557–61.
  10. Hope-Ross M, Yannuzzi LA, Gragoudas ES, et al. Adverse reactions due to indocyanine green. *Ophthalmology* 1994;101:529–33.
  11. Speich R, Saesseli B, Hoffmann U, et al. Anaphylactoid reactions after indocyanine-green administration. *Ann Intern Med* 1988;109:345–6.
  12. Benya R, Quintana J, Brundage B. Adverse reactions to indocyanine green: a case report and a review of the literature. *Cathet Cardiovasc Diagn* 1989;17:231–3.
  13. Iseki K, Onoyama K, Fujimi S, et al. Shock caused by indocyanine green dye in chronic hemodialysis patients. *Clin Nephrol* 1980;14:210.
  14. Flower RW, Csaky KG, Murphy RP. Disparity between fundus camera and scanning laser ophthalmoscope indocyanine green imaging of retinal pigment epithelium detachments. *Retina* 1998;18:260–8.
  15. Wolf S, Wald KJ, Elsner AE, et al. Indocyanine green choroidal videoangiography: a comparison of imaging analysis with the scanning laser ophthalmoscope and the fundus camera. *Retina* 1993;13:266–9.
  16. Stanga PE, Lim JI, Hamilton P. Indocyanine green angiography in chorioretinal diseases: indications and interpretation: an evidence-based update. *Ophthalmology* 2003;110:15–21;quiz 22–3.
  17. Yannuzzi LA, Flower RW, Slakter JS. Indocyanine green angiography. St Louis: Mosby Year Book; 1997: 46.
  18. Hayreh SS. Physiological anatomy of the choroidal vascular bed. *Int Ophthalmol* 1983;6:85–93.
  19. Mutoh T, Sakurai M, Tamai M. Indocyanine green fundus angiography of retrobulbar vasculature. *Arch Ophthalmol* 1995;113:631–3.
  20. Ohno-Matsui K, Morishima N, Ito M, et al. Indocyanine green angiography of retrobulbar vascular structures in severe myopia. *Am J Ophthalmol* 1997;123:494–505.
  21. Gass JD. Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. *Am J Ophthalmol* 1994;118:285–98.
  22. Macular Photocoagulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Guidelines for evaluation and treatment in the macular photocoagulation study. *Arch Ophthalmol* 1991;109:1242–57.

23. Sadda SR, Liakopoulos S, Keane PA, et al. Relationship between angiographic and optical coherence tomographic (OCT) parameters for quantifying choroidal neovascular lesions. *Graefes Arch Clin Exp Ophthalmol* 2010;248:175–84.
24. Freund KB, Ho IV, Barbazetto IA, et al. Type 3 neovascularization: the expanded spectrum of retinal angiomatous proliferation. *Retina* 2008;28: 201–11.
25. Olsen TW, Feng X, Kasper TJ, et al. Fluorescein angiographic lesion type frequency in neovascular age-related macular degeneration. *Ophthalmology* 2004;111:250–5.
26. Guyer DR, Yannuzzi LA, Slakter JS, et al. Classification of choroidal neovascularization by digital indocyanine green videoangiography. *Ophthalmology* 1996;103:2054–60.
27. Yannuzzi LA, Hope-Ross M, Slakter JS, et al. Analysis of vascularized pigment epithelial detachments using indocyanine green videoangiography. *Retina* 1994;14:99–113.
28. Rosenfeld PJ, Brown DM, Heier JS, et al. Ranibizumab for neovascular age-related macular degeneration. *N Engl J Med* 2006;355:1419–31.
29. Massacesi AL, Sacchi L, Bergamini F, et al. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. *Graefes Arch Clin Exp Ophthalmol* 2008;246:89–92.
30. Shiraga F, Ojima Y, Matsuo T, et al. Feeder vessel photocoagulation of subfoveal choroidal neovascularization secondary to age-related macular degeneration. *Ophthalmology* 1998;105:662–9.
31. Staurenghi G, Orzalesi N, La Capria A, et al. Laser treatment of feeder vessels in subfoveal choroidal neovascular membranes: a revisit using dynamic indocyanine green angiography. *Ophthalmology* 1998;105:2297–305.
32. Bottoni F, Massacesi A, Cigada M, et al. Treatment of retinal angiomatous proliferation in age-related macular degeneration: a series of 104 cases of retinal angiomatous proliferation. *Arch Ophthalmol* 2005;123:1644–50.
33. Schmidt-Erfurth U, Kriechbaum K, Oldag A. Three-dimensional angiography of classic and occult lesion types in choroidal neovascularization. *Invest Ophthalmol Vis Sci* 2007;48:1751–60.
34. Watzke RC, Klein ML, Hiner CJ, et al. A comparison of stereoscopic fluorescein angiography with indocyanine green videoangiography in age-related macular degeneration. *Ophthalmology* 2000;107:1601–6.
35. Hlushchuk R, Baum O, Gruber G, et al. The synergistic action of a VEGF-receptor tyrosine-kinase inhibitor and a sensitizing PDGF-receptor blocker depends upon the stage of vascular maturation. *Microcirculation* 2007;14:813–25.
36. Massacesi AL, Sacchi L, Bergamini F, et al. The prevalence of retinal angiomatous proliferation in age-related macular degeneration with occult choroidal neovascularization. *Graefes Arch Clin Exp Ophthalmol* 2008;246:89–92.
37. Hartnett ME, Weiter JJ, Staurenghi G, et al. Deep retinal vascular anomalous complexes in advanced age-related macular degeneration. *Ophthalmology* 1996;103:2042–53.
38. Massacesi AL, Sacchi L, Bergamini F, et al. The prevalence of retinal angiomatous

- proliferation in age-related macular degeneration with occult choroidal neovascularization. *Graefes Arch Clin Exp Ophthalmol* 2008;246:89–92.
39. Viola F, Massacesi A, Orzalesi N, et al. Retinal angiomatous proliferation: natural history and progression of visual loss. *Retina* 2009;29:732–9.
  40. Rouvas AA, Papakostas TD, Vavvas D, et al. Intravitreal ranibizumab, intravitreal ranibizumab with PDT, and intravitreal triamcinolone with PDT for the treatment of retinal angiomatous proliferation: a prospective study. *Retina* 2009;29:536–44.
  41. Saito M, Shiragami C, Shiraga F, et al. Comparison of intravitreal triamcinolone acetate with photodynamic therapy and intravitreal bevacizumab with photodynamic therapy for retinal angiomatous proliferation. *Am J Ophthalmol* 2010;149:472–81.
  42. Yannuzzi LA, Sorenson J, Spaide RF, et al. Idiopathic polypoidal choroidal vasculopathy (IPCV). *Retina* 1990;10:1–8.
  43. Spaide RF, Yannuzzi LA, Slakter JS, et al. Indocyanine green videoangiography of idiopathic polypoidal choroidal vasculopathy. *Retina* 1995;15:100–10.
  44. Yannuzzi LA, Wong DW, Sforzolini BS, et al. Polypoidal choroidal vasculopathy and neovascularized age-related macular degeneration. *Arch Ophthalmol* 1999;117:1503–10.
  45. Ahuja RM, Stanga PE, Vingerling JR, et al. Polypoidal choroidal vasculopathy in exudative and haemorrhagic pigment epithelial detachments. *Br J Ophthalmol* 2000;84:479–84.
  46. Ahuja RM, Downes SM, Stanga PE, et al. Polypoidal choroidal vasculopathy and central serous chorioretinopathy. *Ophthalmology* 2001;108:1009–10.
  47. Yannuzzi LA, Freund KB, Goldbaum M, et al. Polypoidal choroidal vasculopathy masquerading as central serous chorioretinopathy. *Ophthalmology* 2000;107:767–77.
  48. Maruko I, Iida T, Saito M, et al. Combined cases of polypoidal choroidal vasculopathy and typical age-related macular degeneration. *Graefes Arch Clin Exp Ophthalmol* 2010;248:361–8.
  49. Lai TY, Chan WM, Liu DT, et al. Intravitreal bevacizumab (Avastin) with or without photodynamic therapy for the treatment of polypoidal choroidal vasculopathy. *Br J Ophthalmol* 2008;92:661–6.
  50. Eandi CM, Ober MD, Freund KB, et al. Selective photodynamic therapy for neovascular age-related macular degeneration with polypoidal choroidal neovascularization. *Retina* 2007;27:825–31.
  51. Guyer DR, Yannuzzi LA, Slakter JS, et al. Digital indocyanine green videoangiography of central serous chorioretinopathy. *Arch Ophthalmol* 1994;112:1057–62.
  52. Yannuzzi LA, Slakter JS, Gross NE, et al. Indocyanine green angiography-guided photodynamic therapy for treatment of chronic central serous chorioretinopathy: a pilot study. *Retina* 2003;23:288–98.
  53. Piccolino FC, Borgia L. Central serous chorioretinopathy and indocyanine green angiography. *Retina* 1994;14:231–42.

54. Reibaldi M, Cardascia N, Longo A, et al. Standard-fluence versus low-fluence photodynamic therapy in chronic central serous chorioretinopathy: a nonrandomized clinical trial. *Am J Ophthalmol* 2010;149:307–15.
55. Inoue R, Sawa M, Tsujikawa M, et al. Association between the efficacy of photodynamic therapy and indocyanine green angiography findings for central serous chorioretinopathy. *Am J Ophthalmol* 2010;149:441–6.
56. Tsujikawa A, Ojima Y, Yamashiro K, et al. Punctate hyperfluorescent spots associated with central serous chorioretinopathy as seen on indocyanine green angiography. *Retina* 2010;30:801–9.
57. Kitaya N, Nagaoka T, Hikichi T, et al. Features of abnormal choroidal circulation in central serous chorioretinopathy. *Br J Ophthalmol* 2003;87:709–12.
58. Prunte C, Flammer J. Choroidal capillary and venous congestion in central serous chorioretinopathy. *Am J Ophthalmol* 1996;121:26–34.
59. Shields JA, Shields CL. Vascular tumors and malformations of the uvea. In: *Atlas of Intraocular Tumors*. Philadelphia: Lippincott, Williams & Wilkins; 2008:230–51.
60. Mashayekhi A, Shields CL. Circumscribed choroidal hemangioma. *Curr Opin Ophthalmol* 2003;14:142–9.
61. Mantelli F, Bruscolini A, La Cava M, Abdolrahimzadeh S, Lambiase A. Ocular manifestations of Sturge-Weber syndrome: pathogenesis, diagnosis, and management. *Clin Ophthalmol* 2016;10:871–8.
62. Singh AD, Kaiser PK, Sears JE. Choroidal hemangioma. *Ophthalmol Clin North Am* 2005;18:151–61.
63. Arevalo JF, Shields CL, Shields JA, et al. Circumscribed choroidal hemangioma: characteristic features with indocyanine green videoangiography. *Ophthalmology* 2000;107:344–50.
64. Sallet G, Amoaku WM, Lafaut BA, et al. Indocyanine green angiography of choroidal tumors. *Graefes Arch Clin Exp Ophthalmol* 1995;233:677–89.
65. Andersen MV, Scherfig E, Prause JU. Differential diagnosis of choroidal melanomas and nevi using scanning laser ophthalmoscopic indocyanine green angiography. *Acta Ophthalmol Scand* 1995;73:453–6.
66. Mueller AJ, Bartsch DU, Folberg R, et al. Imaging the microvasculature of choroidal melanomas with confocal indocyanine green scanning laser ophthalmoscopy. *Arch Ophthalmol* 1998;116:31–9.
67. Mueller AJ, Freeman WR, Schaller UC, et al. Complex microcirculation patterns detected by confocal indocyanine green angiography predict time to growth of small choroidal melanocytic tumors: MuSIC Report II. *Ophthalmology* 2002;109:2207–14.
68. Schaller UC, Mueller AJ, Bartsch DU, et al. Choroidal melanoma microcirculation with confocal indocyanine green angiography before and 1 year after radiation brachytherapy. *Retina* 2000;20:627–32.
69. Krause L, Bechrakis NE, Heinrich S, et al. Indocyanine green angiography and fluorescein angiography of malignant choroidal melanomas following proton beam

- irradiation. *Graefes Arch Clin Exp Ophthalmol* 2005;243:545–50.
70. Midena E, Pilotto E, de Belvis V et al. Choroidal vascular changes after transpupillary thermotherapy for choroidal melanoma. *Ophthalmology* 2003;110:2216–22.
  71. Annesley WHJ. Peripheral exudative hemorrhagic chorioretinopathy. *Trans Am Ophthalmol Soc* 1980;78:321–64.
  72. Shields CL, Salazar PF, Mashayekhi A, et al. Peripheral exudative hemorrhagic chorioretinopathy simulating choroidal melanoma in 173 eyes. *Ophthalmology* 2009;116:529–35.
  73. Shields JA, Mashayekhi A, Ra S, Shields CL. Pseudomelanomas of the posterior uveal tract: the 2006 Taylor R. Smith Lecture. *Retina*. 2005;25(6):767–71.
  74. Ghassemi F, Bazvand F, Hosseini SS. Pseudomelanoma at a referral center in iran. *J Ophthalmic Vis Res*. 2014;9(1):50–3.
  75. Gross NE, Yannuzzi LA, Freund KB, et al. Multiple evanescent white dot syndrome. *Arch Ophthalmol* 2006;124:493–500.
  76. Dell'omo R, Wong R, Marino M, et al. Relationship between different fluorescein and indocyanine green angiography features in multiple evanescent white dot syndrome. *Br J Ophthalmol* 2010;94:59–63.
  77. Slakter JS, Giovannini A, Yannuzzi LA et al. Indocyanine green angiography of multifocal choroiditis. *Ophthalmology* 1997;104:1813–9.
  78. Fardeau C, Herbort CP, Kullmann N, et al. Indocyanine green angiography in birdshot chorioretinopathy. *Ophthalmology* 1999;106:1928–34.
  79. Trinh L, Bodaghi B, Fardeau C et al. Clinical features, treatment methods, and evolution of birdshot chorioretinopathy in 5 different families. *Am J Ophthalmol* 2009;147:1042–7.
  80. Park D, Schatz H, McDonald HR, et al. Indocyanine green angiography of acute multifocal posterior placoid pigment epitheliopathy. *Ophthalmology* 1995;102:1877–83.
  81. Howe LJ, Woon H, Graham EM, et al. Choroidal hypoperfusion in acute posterior multifocal placoid pigment epitheliopathy. An indocyanine green angiography study. *Ophthalmology* 1995;102:790–8.
  82. Schneider U, Inhoffen W, Gelisken F. Indocyanine green angiography in a case of unilateral recurrent posterior acute multifocal placoid pigment epitheliopathy. *Acta Ophthalmol Scand* 2003;81:72–5.
  83. Giovannini A, Mariotti C, Ripa E, et al. Indocyanine green angiographic findings in serpiginous choroidopathy. *Br J Ophthalmol* 1996;80:536–40.
  84. Amer R, Lois N. Punctate inner choroidopathy. *Surv Ophthalmol* 2011;56:36–53.
  85. Tiffin PA, Maini R, Roxburgh ST, et al. Indocyanine green angiography in a case of punctate inner choroidopathy. *Br J Ophthalmol* 1996;80:90–1.
  86. Rothova A. Ocular involvement in sarcoidosis. *Br J Ophthalmol* 2000;84(1):110–16.
  87. Heiligenhaus A, Wefelmeyer D, Wefelmeyer E, et al. The eye as a common site for the early clinical manifestation of sarcoidosis. *Ophthalmic Res* 2011;46(1):9–12.
  88. Letocha CE, Shields JA, Goldberg RE. Retinal changes in sarcoidosis. *Can J Ophthalmol* 1975;10(2):184–92.